VANCOUVER, British Columbia--(BUSINESS WIRE)--In a large clinical study of adults ages 50 to 59, ZOSTAVAX® (Zoster Vaccine Live), Merck's vaccine for the prevention of shingles (herpes zoster), reduced the incidence of shingles by nearly 70 percent (69.8) compared to placebo. These new data will be presented on Oct. 23 at the 48th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Vancouver, British Columbia, Canada. Based on these results, earlier this year Merck filed a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) for the use of ZOSTAVAX to prevent shingles in people 50 to 59 years of age.
